Inhibikase Therapeutics appoints Scott Wasserman to board of directors
Inhibikase announced Dr. Scott Wasserman is joining its board and an incumbent director, Dennis Berman, is resigning. The move aims to bolster expertise as Inhibikase advances its Phase 3 trial of IKT-001 for Pulmonary Arterial Hypertension.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed